Lormetazepam CF

Lormetazepam CF Uses, Dosage, Side Effects, Food Interaction and all others data.

Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia . It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

Lormetazepam CF is a benzodiazepine which reduces central nervous system (CNS) activity . It produces anxiolytic, muscle relaxant, sedative and hypnotic effects. Because it is a short-acting benzodiapine, it does not produce significant sedation after waking.

Lormetazepam CF
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Lormetazepam CF
Generic	Lormetazepam
Lormetazepam Other Names	(RS)-Lormetazepam, Lormetazepam, Methyllorazepam, N-Methyllorazepam
Type
Formula	C₁₆H₁₂Cl₂N₂O₂
Weight	Average: 335.185 Monoisotopic: 334.027583052
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	Netherlands
Last Updated:	September 19, 2023 at 7:00 am

Uses

Lormetazepam CF is a benzodiazepine indicated in the treatment of anxiety and the induction of anesthesia.

For the treatment of short-term insomnia

Lormetazepam CF is also used to associated treatment for these conditions: Severe Insomnia, Sleep Disorder, Acute Anxiety

How Lormetazepam CF works

Lormetazepam CF, as a benzodiazepine, binds to the regulatory site between the α and γ subunits of γ-aminobutryic acid (GABA) A receptors with γ2 and α1, α2, α3, or α5 subunits . This facilitates the opening of the chloride channel allowing chloride ions to flow into the neuron resulting in hyperpolarization. Hyperpolarized neurons require greater simulation to reach their action potential threshold. The general inhibitory effect on neuronal depolarization produces the effects of lormetazepam.

Toxicity

The primary manifestation of overdosage ranges from drowsiness to coma and symptoms may include ataxia, hypotension, hypotonia, respiratory depression which may lead to death .

Experimental LD50 values are as follows : Mouse - 780 mg/kg (intraperitoneal), 1790 mg/kg (oral), 10000 mg/kg (subcutaneous). Rat - 6250 mg/kg (intraperitoneal), 10000 mg/kg (oral), 10000 mg/kg (intraperitoneal).